Talazoparib

Category: Cancer



Talazoparib Overview

Talazoparib (trade name Talzenna, BMN-673) is an orally available poly ADP ribose polymerase (PARP) inhibitor currently in development by Pfizer for the treatment of advanced breast cancer patients with germline BRCA mutations.[1] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[2][3] The U.S. FDA approved Talzenna (talazoparib) for patients with a germline BRCA-mutated, HER2-negative locally advanced or metastatic breast c...

Read more Talazoparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Talazoparib

Recent Talazoparib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Talazoparib
  • Capsule: 0.25mg, 1mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Talazoparib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA